BridgeBio outlines transition to cash generation by 2028 with $600M profit target, driven by pipeline advances and Attruby growth
Source: SeekingAlpha
2026-02-24 19:28:32 ET
More on BridgeBio Pharma
- BridgeBio Pharma, Inc. (BBIO) Q4 2025 Earnings Call Transcript
- BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase 3 PROPEL 3 Results for Infigratinib in Children With Achondroplasia Transcript
- BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase 3 PROPEL 3 Results for Infigratinib in Children With Achondroplasia - Slideshow
- BridgeBio rises after late-stage trial win for dwarfism therapy
- BridgeBio Pharma prices $550M convertible bond offering
Read the full article on Seeking Alpha
For further details see:
BridgeBio outlines transition to cash generation by 2028 with $600M profit target, driven by pipeline advances and Attruby growth
BridgeBio Pharma Inc.
NASDAQ: BBIO
BBIO Trading
11.99% G/L:
$73.43 Last:
2,577,187 Volume:
$66.12 Open:
BBIO Latest News
March 04, 2026 07:30:00 am
BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference
February 24, 2026 04:01:00 pm
BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates
BBIO Stock Data
$13,905,867,946
157,635,809
2.34%
155
N/A
Biotechnology & Life Sciences
Healthcare
US
Palo Alto
